# Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide

> **NCT01533116** · PHASE1 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 52 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** BIA 9-1067
- **DRUG:** Placebo
- **DRUG:** levodopa/carbidopa
- **DRUG:** levodopa/benserazide

## Key facts

- **NCT ID:** NCT01533116
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2009-08
- **Final completion:** 2010-03
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2015-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01533116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01533116, "Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01533116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*